Madrid, Spain – 1 September 2025: After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to ...

After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to late-breaking research presented in a Hot Line ...

MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) failure among patients who undergo coronary artery bypass surgery, the ...

SAN FRANCISCO, CA—For patients with failed saphenous vein grafts (SVGs) after CABG, performing PCI to open up the graft appears to be the better course of action over intervening on the bypassed ...

Medical procedures for coronary artery disease include angioplasty, which uses balloons and stents to open blocked arteries, and bypass surgery, which creates new pathways around blockages using ...

Please provide your email address to receive an email when new articles are posted on . Patients with prior bypass surgery who need PCI had better 1-year results when the procedure was performed on ...

Perioperative morbidity and mortality are slightly reduced with coronary artery bypass grafting (CABG) performed off-pump (OPCAB) by experienced surgeons, according to a study presented at the annual ...